The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks

Betschel SD, Caballero T, Jones DH, Longhurst HJ, Manning M, van Kooten S, Heckmann M, Danese S, Goga L, Burnette AF
Allergy, Asthma & Clinical Immunology

Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

Riedl MA, Farkas H, Aygören-Pürsün E, Psarros F, Soteres DF, M.D., Staevska M, Cancian M
New England Journal of Medicine

Sebetralstat: A Rapidly Acting Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema

Feener EP, Davie RL, Murugesan N, Pethen SJ, Hampton SL, Smith MD, Audhya PK, Yea CM

Drugs and Drug Candidates

Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation

Clermont AC, Murugesan N, Edwards HJ, Lee DK, Bayliss NP, Duckworth EJ, Pethen SJ, Hampton SL, Gailani D, Feener EP

Frontiers in Pharmacology

Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat

Cohn DM, Aygören-Pürsün E, Bernstein JA, Farkas H, Lumry WR, Maurer M, Zanichelli A, Iverson M, Hao J, Smith MD, Yea CM, Audhya PK, Riedl MA

2023 Clinical and Translation Allergy

Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On Demand Treatment for Hereditary Angiodema

Davie R, Edwards H, Evans D, Hodgson S, Stocks M, Smith A, Rushbrooke L, Pethen S, Roe M, Clark D, McEwan P, Hampton S

PMID: 36251573

Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900 following a single oral does in healthy male participants

Mutch P, Bashir M, Jung B, Yi P, Iverson M

PMID: 36200371

KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results

Maetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, Yea CM

PMID: 35086692

Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.

Clinical & Experimental Allergy

One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study

Sun JK, Maturi RK, Boyer DS, Wells JA, Gonzalez VH, Tansley R, Hernandez H, Maetzel A, Feener EP, Aiello LP.
OPHTHALMOLOGY RETINA